Shares of United Therapeutics (UTHR) and Liquidia (LQDA) are moving sharply in opposite directions in Friday afternoon trading. Shares of United are up $20.42, or 7%, to $295.12 at time of writing, while Liquidia shares have fallen $1.62, or 9%, to $17.07. United Therapeutics and Liquidia have been engaged in a legal fight related to United’s ‘327 patent as United has been trying to keep a Tyvaso competitor called Yutrepia off the market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment
- United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study
- United Therapeutics’ PAH Study Update: Implications for Investors
- Buy Rating for United Therapeutics Driven by Anticipated Growth in IPF Market and Strong Market Position
- United Therapeutics announces $1B accelerated share repurchase program